
Enrolling Now!
Amended to allow immunotherapy for induction/maintenance therapy and surgery for local consolidation
All Protocol Documents are posted on the CTSU website – www.ctsu.org

Key Eligibility Criteria

- Pathologically proven NSCLC diagnosis with metastases (Stage IV disease)
- Patients must have received first-line/induction systemic therapy with immunotherapy and/or platinum-based chemotherapy (a total of 4 cycles or courses) and achieved stable disease or a partial response
- Patients must have measurable disease at baseline and 3 or fewer discrete, extracranial metastatic disease sites that are technically amenable to SBRT or resection (at least one disease site must be amenable to radiation) at registration
- Patients with brain metastases are eligible if intracranial disease is treated prior to registration and as long as there is extracranial disease (metastases and/or primary)

Study Schema

Randomization will be 2:1 in favor of RT (N=400)*

<table>
<thead>
<tr>
<th>Arm 1</th>
<th>Arm 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maintenance systemic therapy alone**</td>
<td>SBRT or SBRT and Surgery to all sites of metastases plus irradiation (SBRT or hypofractionated RT) of the primary site followed by maintenance systemic therapy</td>
</tr>
</tbody>
</table>

*Stratification: histology (squamous vs. non-squamous), systemic therapy (immunotherapy vs. cytotoxic chemotherapy).
** Selection of regimen is at the discretion of the treating physician in agreement with the patient. Acceptable immunotherapy for NRG-LU002 is pembrolizumab either alone or in combination with pemetrexed and platinum therapy.

Study Principal Investigator:

Puneeth Iyengar, MD, PhD
UT Southwestern Medical Center
puneeth.iyengar@utsouthwestern.edu

Please refer to the protocol cover pages for NRG Oncology topic-specific contact information.